Lv1
90 积分 2026-03-17 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2天前
已采纳
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2天前
已驳回
Protein kinase Cι-driven macrophage infiltration mediates immunosuppression in non-small cell lung cancer
2天前
已采纳
皖公网安备34019202002308
